Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Upwork Inc (UPWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Upwork Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $26.2 (market cap $4.49B), while Upwork Inc trades at $8.79 (market cap $1.10B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 4.1× Upwork Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | UPWK | |
|---|---|---|
Market Cap | $4.49B | $1.10B |
Sector | Health | Industrials |
52-Week High | $28.06 | $22.11 |
52-Week Low | $20.06 | $7.84 |
Enterprise Value | $3.69B | $895.35M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
UPWK trades at $8.87, down 3.17% today, with a bullish technical signal from moving averages and ADX indicators. The company reported $787.78M revenue in 2025 with a net income margin of 14.65%, though recent quarters show earnings misses. Positive developments include a new AI partnership with Claude announced June 17, 2026, while legal investigations into securities violations pose headwinds.
The stock presents a mixed outlook: valuation ratios like P/E of 10.94 and EV/EBITDA of 5.8 suggest potential upside to the $10.67 consensus target, but earnings volatility and legal risks require caution. Growth in the gig economy supports long-term opportunity, yet investor sentiment is tempered by recent guidance cuts and shareholder lawsuits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
